Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its 2025 Annual Meeting of Stockholders scheduled for Thursday, March 20, 2025, at 10:00 a.m. Pacific Time. The meeting will be conducted in a virtual format.
The event will feature two main segments: first, the formal business and voting portion, followed by an investor presentation and corporate update by Chairman and CEO Dr. Amit Kumar. A question-and-answer session will conclude the meeting. The company has made the meeting accessible to all interested parties through their virtual platform at www.virtualshareholdermeeting.com/ANIX2025.
Anixa Biosciences (NASDAQ: ANIX), un'azienda biotecnologica specializzata nel trattamento e nella prevenzione del cancro, ha annunciato la sua Assemblea Annuale degli Azionisti 2025 programmata per giovedì 20 marzo 2025, alle 10:00 ora del Pacifico. L'incontro si svolgerà in formato virtuale.
L'evento comprenderà due segmenti principali: prima, la parte formale di affari e votazione, seguita da una presentazione per gli investitori e un aggiornamento aziendale a cura del Presidente e CEO Dr. Amit Kumar. Una sessione di domande e risposte concluderà l'incontro. L'azienda ha reso l'incontro accessibile a tutte le parti interessate attraverso la loro piattaforma virtuale su www.virtualshareholdermeeting.com/ANIX2025.
Anixa Biosciences (NASDAQ: ANIX), una empresa de biotecnología especializada en el tratamiento y prevención del cáncer, ha anunciado su Reunión Anual de Accionistas 2025 programada para el jueves 20 de marzo de 2025, a las 10:00 a.m. Hora del Pacífico. La reunión se llevará a cabo en formato virtual.
El evento contará con dos segmentos principales: primero, la parte formal de negocios y votación, seguida de una presentación para inversores y una actualización corporativa a cargo del Presidente y CEO Dr. Amit Kumar. Una sesión de preguntas y respuestas concluirá la reunión. La empresa ha hecho que la reunión sea accesible para todas las partes interesadas a través de su plataforma virtual en www.virtualshareholdermeeting.com/ANIX2025.
Anixa Biosciences (NASDAQ: ANIX), 암 치료 및 예방을 전문으로 하는 생명공학 회사가 2025년 주주 연례 회의를 2025년 3월 20일 목요일 오전 10시(태평양 표준시)로 예정했다고 발표했습니다. 이 회의는 가상 형식으로 진행됩니다.
이 행사는 두 개의 주요 세그먼트로 구성됩니다: 먼저, 공식 비즈니스 및 투표 부분, 그 다음으로 회장 겸 CEO Dr. Amit Kumar의 투자자 프레젠테이션 및 기업 업데이트가 이어집니다. 질문 및 답변 세션이 회의를 마무리합니다. 회사는 www.virtualshareholdermeeting.com/ANIX2025의 가상 플랫폼을 통해 모든 이해관계자가 회의에 접근할 수 있도록 했습니다.
Anixa Biosciences (NASDAQ: ANIX), une entreprise de biotechnologie spécialisée dans le traitement et la prévention du cancer, a annoncé sa Réunion Annuelle des Actionnaires 2025 prévue pour le jeudi 20 mars 2025, à 10h00, heure du Pacifique. La réunion se déroulera en format virtuel.
L'événement comportera deux segments principaux : d'abord, la partie formelle des affaires et du vote, suivie d'une présentation pour les investisseurs et d'une mise à jour de l'entreprise par le Président et CEO Dr. Amit Kumar. Une session de questions-réponses conclura la réunion. L'entreprise a rendu la réunion accessible à toutes les parties intéressées via leur plateforme virtuelle à www.virtualshareholdermeeting.com/ANIX2025.
Anixa Biosciences (NASDAQ: ANIX), ein Biotechnologieunternehmen, das sich auf die Behandlung und Prävention von Krebs spezialisiert hat, hat seine Jahreshauptversammlung der Aktionäre 2025 für Donnerstag, den 20. März 2025, um 10:00 Uhr Pazifischer Zeit angekündigt. Die Versammlung wird in virtueller Form stattfinden.
Die Veranstaltung wird aus zwei Hauptsegmenten bestehen: Zuerst der formelle Geschäfts- und Abstimmungsteil, gefolgt von einer Investorenpräsentation und Unternehmensaktualisierung durch Vorsitzenden und CEO Dr. Amit Kumar. Eine Frage-und-Antwort-Runde wird die Versammlung abschließen. Das Unternehmen hat die Versammlung für alle interessierten Parteien über ihre virtuelle Plattform unter www.virtualshareholdermeeting.com/ANIX2025 zugänglich gemacht.
- None.
- None.
Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a question-and-answer session. All interested parties may attend the Meeting.
All parties may access the Meeting online at www.virtualshareholdermeeting.com/ANIX2025.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-2025-annual-meeting-of-stockholders-to-include-investor-presentation-open-to-all-interested-parties-302396784.html
SOURCE Anixa Biosciences, Inc.
FAQ
When is Anixa Biosciences (ANIX) 2025 Annual Meeting of Stockholders?
How can investors attend Anixa Biosciences (ANIX) 2025 Annual Meeting?
What will be presented at Anixa Biosciences (ANIX) 2025 Annual Meeting?
Is Anixa Biosciences (ANIX) 2025 Annual Meeting open to non-shareholders?
